The Europe Narcolepsy Therapeutics Market would witness market growth of 9.1% CAGR during the forecast period (2022-2028).
Narcolepsy frequently causes the most difficulties and is the first symptom to manifest, making it challenging to focus on particular tasks. Other signs include a sudden, waking muscular weakness that renders a person immobile or lame. Although narcolepsy is a chronic condition that cannot be fully treated, the symptoms can gradually become better with the right drugs and a lifestyle change.
Individuals who experience more stress live stressful lives as a result, which raises their risk of developing narcolepsy by increasing their use of dangerous addictive like alcohol, tobacco, and other substances. Over the past few years, narcolepsy drug development has accelerated significantly. Narcoleptics have a strong want to sleep and are low on energy. Cataplexy is an abrupt loss of muscle tone and weakness that might last for a few seconds or several minutes.
This is the first face-to-face survey conducted across the entire country of Germany on the prevalence of clearly characterized severe insomnia and how it affects people's quality of life. The survey was a component of an epidemiological investigation that was also carried out in Sweden, Belgium, Great Britain, and Ireland. The quota approach was used to interview a representative sample of 1913 adults in all regions of Germany who were at least 18 years old. The fourth revision of the Diagnostic and Statistical Manual of Mental Diseases' primary criteria for severe insomnia was used to determine which subjects met the criteria for symptomatic insomnia (DSM-IV).
The Germany market dominated the Europe Narcolepsy Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $361.2 million by 2028.The UK market is anticipated to grow at a CAGR of 8.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 9.9% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Narcolepsy Therapeutics Market will Hit $5 Billion by 2028, at a CAGR of 10.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
By Type
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 